Researchers testing CAR T-Cell therapy to treat multiple sclerosis
UC expert featured in Precision Medicine Online article
The University of Cincinnati's Aram Zabeti was featured in a Precision Medicine Online article discussing a new trial testing CAR T-cell therapy to treat multiple sclerosis.
UC is a trial site for the Phase 1 Breakfree-2 trial, sponsored by Bristol Myers Squibb. MS occurs when the immune system mistakenly attacks the myelin that protects and covers nerve fibers, disrupting the communication between the brain and the rest of the body and leading to a wide range of symptoms.
In CAR T-cell therapy, patient's immune cells are collected and genetically modified to recognize and eliminate the malfunctioning immune cells that drive MS. Once modified, they are infused back into the patient.
"We want to make sure they're safe," and that the new cells do not cause additional harm or damage, said Zabeti, associate professor of neurology at UC’s College of Medicine and director of the Waddell Center for MS. "We're hoping [patients] might not need any re-treatment," he added, but that's an area in need of further study.
Read the Precision Medicine Online article.
Read more about the trial at UC.
For more information on trial eligibility and enrollment for this and other MS trials open at UC, please contact trial coordinator Sara Esmaeli at esmaeisr@ucmail.uc.edu.
Featured photo at top illustrating CAR-T cells attacking a malfunctioning immune cell. Photo/selvanegra/iStock Photo.
Related Stories
CCM welcomes new film and media scoring faculty member J.R. Paredes
May 20, 2026
UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of J.R. Paredes as CCM's new Assistant Professor of Film and Media Scoring. His faculty appointment officially begins on Aug. 15, 2026. Paredes is a composer, music producer and audio post-production specialist whose work spans film, television and commercial music. His credits include original scores for feature films and series distributed on platforms such as Apple TV+ and Prime Video, as well as extensive work in sound design and mixing for film and media.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.